Form SC 13G Janux Therapeutics, Inc. Filed by: Bregua Corp
- Wall Street surges to all-time closing high on earnings, economic revival
- Was Intel's (INTC) Second Quarter a Speedbump or Inflection?
- Twitter (TWTR) Gains After Beating Q2 Estimates, Analysts Raise PTs as Brand Recovery Accelerates
- U.S. dollar on track for second week of gains; Fed meeting in focus
- Snap (SNAP) Surges 17% After Smashing Q2 Views Across the Board to Yield a Dozen Price Target Hikes
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Janux Therapeutics, Inc.
(Name of Issuer)
(Title of Class of Securities)
June 15, 2021
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|CUSIP No. 47103J 105||13G||Page 2 of 5 Pages|
Names of Reporting Persons
Check the Appropriate Box if a Member of a Group (see instructions)
(a) ☐ (b) ☐
SEC USE ONLY
Citizenship or Place of Organization
British Virgin Islands
Sole Voting Power
Shared Voting Power
Sole Dispositive Power
Shared Dispositive Power
Aggregate Amount Beneficially Owned by Each Reporting Person
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see ☐ instructions)
Percent of Class Represented by Amount in Row 9
Type of Reporting Person (see instructions)
(1) The percentage calculation assumes that there are currently 41,611,510 outstanding shares of Common Stock of the Issuer, based upon the closing of the Issuers initial public offering, as reported in the Issuers prospectus filed with the Securities and Exchange Commission on June 11, 2021.
|CUSIP No. 47103J 105||13G||Page 3 of 5 Pages|
|Item 1.|| |
Name of Issuer
Janux Therapeutics, Inc., a Delaware corporation
Address of Issuers Principal Executive Offices
11099 N. Torrey Pines Road
La Jolla, CA 92037
|Item 2.|| |
Name of Person Filing
Address of Principal Business Office or, if none, Residence
Wickhams Cay, P.O. Box 146, Road Town
Tortola, VG 1110, BVI
British Virgin Islands
Title of Class of Securities
|Item 3.|| |
|Item 4.|| |
Amount Beneficially Owned: 3,749,250 shares of Common Stock
Percent of Class: 9.0%
Number of shares as to which the person has:
Sole power to vote or to direct the vote: 3,749,250
Shared power to vote or to direct the vote: 0
Sole power to dispose or to direct the disposition of: 3,749,250
Shared power to dispose or to direct the disposition of: 0
|Item 5.|| |
Ownership of Five Percent or Less of a Class
|CUSIP No. 47103J 105||13G||Page 4 of 5 Pages|
|Item 6.|| |
Ownership of More than Five Percent on Behalf of Another Person
|Item 7.|| |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
|Item 8.|| |
Identification and Classification of Members of the Group
|Item 9.|| |
Notice of Dissolution of a Group
|Item 10.|| |
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
|CUSIP No. 47103J 105||13G||Page 5 of 5 Pages|
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representatives authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties for whom copies are to be sent.
Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Janux Therapeutics Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer
- After-Hours Stock Movers 07/21: (CSX) (POSH) Higher; (NTGR) (TXN) (THC) Lower (more...)
- Cohen's Point72 Asset Management, L.P. Shows New 5.7% Stake in Poshmark (POSH)
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!